The aim of this study is to evaluate the effects of chronic beta-blocking therapy (atenolol 100 mg/d) on ECG and ECG indexes of left ventricular hypertrophy (LVH) in hypertensive patients. Seventy one subjects with essential hypertension (mean age 47 y) were studied for 5 years. Sokolow-Lyon voltage criteria for ECGLVH (S wave in V1 plus R wave in V5 greater than or equal to 35 mm) were employed in: 38 treated patients with ECGLVH, 12 treated patients without ECGLVH and 21 untreated patients with ECGLVH. Beta-blocking therapy significantly reduced blood pressure (BP) in the treated patients. In the patients with ECGLVH, treatment significantly improved Sokolow-Lyon Index (SLI) reducing it from 55.04 +/- 16.2 mm to 47.6 +/- 15.04 mm (p less than 0.05) but only 11.4% of the treated patients returned within the normality range (SLI less than 35 mm). No significant change was present in the treated patients without ECGLVH. On the contrary, the group of untreated patients showed an increase in SLI from 45.19 +/- 7.08 mm to 50.52 +/- 11.09 mm (p less than 0.05) and no change in hypertension levels. We conclude, therefore, that: ineffective BP control allows progression of LVH; BP reduction by beta-blocking drugs reduces LVH but does not produce complete regression of the hypertrophy, if not in the early stages; if no LVH is present, BP control by these drugs prevents LVH. We emphasize the importance of early detection and treatment of hypertension

Chronic beta 1-blockade and control of left ventricular hypertrophy in hypertension

FOGARI, ROBERTO;
1987-01-01

Abstract

The aim of this study is to evaluate the effects of chronic beta-blocking therapy (atenolol 100 mg/d) on ECG and ECG indexes of left ventricular hypertrophy (LVH) in hypertensive patients. Seventy one subjects with essential hypertension (mean age 47 y) were studied for 5 years. Sokolow-Lyon voltage criteria for ECGLVH (S wave in V1 plus R wave in V5 greater than or equal to 35 mm) were employed in: 38 treated patients with ECGLVH, 12 treated patients without ECGLVH and 21 untreated patients with ECGLVH. Beta-blocking therapy significantly reduced blood pressure (BP) in the treated patients. In the patients with ECGLVH, treatment significantly improved Sokolow-Lyon Index (SLI) reducing it from 55.04 +/- 16.2 mm to 47.6 +/- 15.04 mm (p less than 0.05) but only 11.4% of the treated patients returned within the normality range (SLI less than 35 mm). No significant change was present in the treated patients without ECGLVH. On the contrary, the group of untreated patients showed an increase in SLI from 45.19 +/- 7.08 mm to 50.52 +/- 11.09 mm (p less than 0.05) and no change in hypertension levels. We conclude, therefore, that: ineffective BP control allows progression of LVH; BP reduction by beta-blocking drugs reduces LVH but does not produce complete regression of the hypertrophy, if not in the early stages; if no LVH is present, BP control by these drugs prevents LVH. We emphasize the importance of early detection and treatment of hypertension
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/438326
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact